Trial Profile
Evaluation of Ruxolitinib And Thalidomide Combination as a Therapy for Patients With Myelofibrosis
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Mar 2024
Price :
$35
*
At a glance
- Drugs Ruxolitinib (Primary) ; Thalidomide (Primary)
- Indications Myelofibrosis
- Focus Therapeutic Use
- 01 Mar 2024 Planned End Date changed from 1 Feb 2024 to 1 Feb 2025.
- 01 Mar 2024 Planned primary completion date changed from 1 Feb 2024 to 1 Feb 2025.
- 28 Apr 2023 Planned End Date changed from 1 Feb 2023 to 1 Feb 2024.